The Code, Part 2: Does the ability to more easily change the blueprint of life mean we’re on the path to repairing the broken bits in our genetic inheritance? Or have we tried this before and failed?
Direct to consumer testing can potentially be quite dangerous without appropriate regulations and support to fully understand the implications of the information a consumer receives.
A literature review finds an increased risk of cancer, late-stage cancer, and mortality, with increased waiting time between a positive screening and start of diagnostic testing.
A drug combination has been discovered that could potentially reverse disease symptoms by adjusting natural cellular functions.
23andMe CEO and co-founder Anne Wojcicki says consumers don’t need experts to interpret results from genetic risk tests, and compared the information her company offers to at-home pregnancy tests. But is it that simple?
Researchers have used CRISPR to develop a pig model of Huntington’s disease that better mimics how the disease progresses in humans.
Concerningly, 20% of publicly funded cancer clinical trials in the United States fail because investigators are unable to enroll enough participants.
Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has secured a $60 million Series A+ financing.
With the demand for direct-to-consumer genetic tests on the rise, a new analysis has questioned how reliable the results really are.
Healthcare tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.
Home genetic tests like AncestryDNA and 23andMe are more popular than ever. But having widespread access to personal genetic information—without the knowledge of how to interpret results—can lead to problems.